Conference data and funding moves put lorundrostat in focus

Mineralys Therapeutics (MLYS) has drawn fresh attention after highlighting new post hoc biomarker data on its lead candidate lorundrostat in uncontrolled hypertension, ahead of presentations at ENDO 2026 and the Goldman Sachs Global Healthcare Conference.

The company recently combined this clinical spotlight with sizeable new funding, including a US$150.0 million follow on equity offering and access to up to US$500.0 million in senior secured term loans tied to lorundrostat development and commercialization milestones.

At a share price of US$23.76, Mineralys has seen short term share price pressure, with the 30 day share price return down 20.08% and the year to date share price return down 33.46%. However, the 1 year total shareholder return of 52.80% and 3 year total shareholder return of 48.97% suggest investors who stayed the course have still seen solid gains as recent funding moves and upcoming conference presentations reset expectations around lorundrostat and future execution.

If this kind of biotech news has your attention, it can be worth widening your view to other healthcare companies using AI to tackle complex conditions, starting with the 39 healthcare AI stocks.

With Mineralys now funded through key lorundrostat milestones and trading at a steep intrinsic discount, the real question for you is simple: is this a fresh opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 53.3% Undervalued

Compared to the narrative fair value of $50.88, the last close of $23.76 reflects a wide gap that hinges on lorundrostat successfully shifting Mineralys from zero revenue to a commercial profile.

Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.

Curious what assumptions sit behind a fair value more than double the current price? Revenue ramp, margin lift and a rich future earnings multiple all play a role. The full narrative spells out how those moving parts fit together.

Result: Fair Value of $50.88 (UNDERVALUED)

However, this hinges on lorundrostat clearing regulatory hurdles and competing effectively, while ongoing losses and future funding needs could strain shareholder returns.

Next Steps

If this mix of upside and risk sounds finely balanced, it may be a good time to move quickly, review the data yourself, and decide where you stand using the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If lorundrostat has sparked your interest, do not stop here. Widen your search and let high quality screeners surface other stocks that fit your playbook.

• Target resilient balance sheets by reviewing companies in the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for quality at attractive prices by scanning the 47 high quality undervalued stocks.
• Spot smaller opportunities with potential by checking the 25 elite penny stocks with strong financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.